Stockscreener 앱 받기
23.90
0.58%
-0.14
시간 외 거래:
23.90
Travere Therapeutics Inc 주식(TVTX)의 최신 뉴스
How to use a screener to detect Travere Therapeutics Inc. breakoutsGap Up & Risk Controlled Stock Alerts - newser.com
Travere Therapeutics (NASDAQ:TVTX) Trading Down 7.6%What's Next? - MarketBeat
Travere therapeutics CAO Calvin Sandra sells $17,520 in stock - MSN
Published on: 2025-09-29 13:53:58 - newser.com
Published on: 2025-09-29 12:50:11 - newser.com
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Using data tools to time your Travere Therapeutics Inc. exitJuly 2025 Setups & Safe Swing Trade Setup Alerts - newser.com
Can trapped investors hope for a rebound in Travere Therapeutics Inc.Weekly Trade Analysis & Proven Capital Preservation Tips - newser.com
Heatmap analysis for Travere Therapeutics Inc. and competitorsPortfolio Value Summary & Weekly Watchlist of Top Performers - newser.com
Travere therapeutics CEO Eric M. Dube sells $273,455 in stock - MSN
Is GAIL India Limited One of the Top Picks for Growth Investors in YEARFlag and Pennant Patterns & Free Phenomenal Trading Returns - earlytimes.in
Published on: 2025-09-28 13:45:23 - earlytimes.in
Published on: 2025-09-28 02:30:57 - newser.com
Travere Therapeutics Inc Stock Analysis and ForecastMarket Profile Overview & Double Digit Returns - earlytimes.in
Travere Therapeutics Forms Golden Cross, Signaling Bullish Breakout Ahead - Markets Mojo
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy - Sharecast News
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) Insider Sells 10,000 Shares of Stock - MarketBeat
Travere Therapeutics' (TVTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Wall Street Zen Downgrades Travere Therapeutics (NASDAQ:TVTX) to Hold - MarketBeat
Travere Therapeutics, Inc. $TVTX Shares Acquired by Assenagon Asset Management S.A. - MarketBeat
H.C. Wainwright reiterates Buy rating on Travere Therapeutics stock - Investing.com
Travere Therapeutics (NASDAQ:TVTX) Downgraded by Wall Street Zen to “Hold” - Defense World
Travere Therapeutics (TVTX): Evaluating Valuation After FDA Fast-Track and Positive FILSPARI Study Results - Sahm
Travere Therapeutics (NASDAQ:TVTX) Earns Buy Rating from HC Wainwright - Defense World
Travere Therapeutics Inc. stock momentum explainedJuly 2025 Review & Long Hold Capital Preservation Plans - newser.com
Sector ETF performance correlation with Travere Therapeutics Inc.July 2025 Technicals & Community Supported Trade Ideas - newser.com
MACD Signal: How sensitive is Travere Therapeutics Inc. to inflation2025 Winners & Losers & Free Reliable Trade Execution Plans - خودرو بانک
HC Wainwright & Co. Reiterates Buy Rating for Travere Therapeuti - GuruFocus
Trading Action: Does Travere Therapeutics Inc. stock have upside surprise potential2025 Investor Takeaways & Reliable Volume Spike Trade Alerts - خودرو بانک
Whale Trades: Can Travere Therapeutics Inc. be the next market leaderWeekly Gains Report & Risk Managed Investment Signals - خودرو بانک
Nephrotic Syndrome Market Analysis: Epidemiology Insights, Therapies, Companies, DelveInsight | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers - Barchart.com
Can Travere Therapeutics Inc be the next market leaderQuarterly Growth Report & Breakout Confirmation Alerts - khodrobank.com
Travere Therapeutics Inc. stock outlook for YEARPortfolio Risk Summary & Real-Time Volume Trigger Notifications - newser.com
Stifel Nicolaus Increases Travere Therapeutics (NASDAQ:TVTX) Price Target to $25.00 - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Given New $35.00 Price Target at Wells Fargo & Company - MarketBeat
Live market analysis of Travere Therapeutics Inc.Weekly Risk Report & Community Consensus Picks - newser.com
Travere rises as FDA says no AdCom required for Filspari label expansion - MSN
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA - MSN
FDA Drops Advisory Committee for Travere’s FILSPARI Review - MSN
Woodline Partners LP Sells 884,278 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics (TVTX) Awaits FDA Decision as FILSPARI Shows Promising Clinical Results - Sahm
Signal Recap: Whats the analyst consensus on Travere Therapeutics IncExit Point & Safe Entry Zone Identification - خودرو بانک
Quarterly Recap: Is Travere Therapeutics Inc.’s growth already priced in2025 Retail Activity & Stepwise Swing Trade Plans - خودرو بانک
Highs Report: Is Travere Therapeutics Inc subject to activist investor interestDay Trade & Free Long-Term Investment Growth Plans - خودرو بانک
Travere Therapeutics (NASDAQ:TVTX) Stock Price Down 4.8%Time to Sell? - MarketBeat
Institution Moves: What is Travere Therapeutics Incs debt to equity ratioGDP Growth & Stock Market Timing Techniques - خودرو بانک
Aug Highlights: How liquid is Travere Therapeutics Inc stockJuly 2025 Price Swings & Stock Market Timing Techniques - خودرو بانک
Short Covering: Is Cuprina Holdings Cayman Limited a turnaround storyTrade Entry Report & AI Enhanced Execution Alerts - khodrobank.com
Travere Therapeutics Stock Soars Pre-market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug Application - MSN
Travere Therapeutics (TVTX) Is Up 8.5% After FDA Removes Advisory Panel Step for FILSPARI in FSGS - Sahm
Travere Therapeutics Sees Unusually Large Options Volume (NASDAQ:TVTX) - MarketBeat
Polar Asset Management Partners Inc. Invests $304,000 in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics: Buy Rating On Back Of Filspari Expansion Towards FSGS (NASDAQ:TVTX) - Seeking Alpha
TVTX: Stifel Raises Price Target to $25, Maintains Hold Rating | TVTX Stock News - GuruFocus
Travere Therapeutics (NASDAQ:TVTX) Reaches New 1-Year HighHere's What Happened - MarketBeat
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4 - MarketScreener
Travere Therapeutics, Inc. $TVTX Shares Sold by Parkman Healthcare Partners LLC - MarketBeat
2.36%
1.10%
자본화:
|
볼륨(24시간):